Estimating survival benefit in castrate metastatic prostate cancer: Decision making in proceeding to a definitive phase III trial
Molecular Diagnostic Techniques
Molecular Targeted Therapy
A hypothesis test using the 75% upper confidence bound to define the lower limit of acceptable clinical activity demonstrates that the 1-year survival probability on Taxol/estramustine/carboplatin is greater than that of the historical population, and hence should be taken into a definitive trial. The design provides investigators increased confidence in making this decision.